Endologix, Inc. (ELGX) updated its FY12 earnings guidance on Thursday. The company provided EPS guidance of ($0.24)-(0.20) for the period.

A number of analysts have recently weighed in on ELGX shares. Analysts at Oppenheimer reiterated an outperform rating on shares of Endologix in a research note to investors on Monday, September 10th. On a related note, analysts at BMO Capital Markets initiated coverage on shares of Endologix in a research note to investors on Friday, September 7th. They set an outperform rating and a $15.00 price target on the stock. Finally, analysts at Piper Jaffray upgraded shares of Endologix from a neutral rating to an overweight rating in a research note to investors on Thursday, August 9th. They now have a $16.00 price target on the stock.

Shares of Endologix, Inc. (ELGX) traded down 0.98% during mid-day trading on Thursday, hitting $13.19. Endologix, Inc. (ELGX) has a one year low of $10.00 and a one year high of $15.77. The company’s market cap is $809.3 million.

Endologix last issued its quarterly earnings data on Thursday, October 25th. The company reported ($0.03) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.04) by $0.01. Endologix’s revenue was up 19.7% compared to the same quarter last year. On average, analysts predict that Endologix, Inc. (ELGX) will post $-0.24 earnings per share for the current fiscal year.

Endologix, Inc. develops, manufactures, markets and sells treatments for aortic disorders. The Company’s product, the Powerlink System is a minimally invasive device for the treatment of abdominal aortic aneurysm (AAA).

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.